Progenza is a patented off-the-shelf stem cell technology.
Showing 25 of 840
CardioCel is becoming a surgeon-preferred biomaterial for heart valve repair.
Cellmid to date has derived over $1.2 million from the midkine diagnostics license.
Zelda has been re-rated in recent weeks as the company continues to deliver on milestones.
Zelda was spun out of a successful U.S. based medicinal cannabis group - Aunt Zelda’s.
Zelda reports positive results of its initial proof of concept study.
Cellmid has two business segments, consumer health and its midkine (MK) portfolio.
Mergers and acquisitions are increasing in the fibrosis and NASH space.
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Anteo Group is a global nano-chemistry technology and medical supply group.
OncoSil Medical Ltd has been receiving a lot of broker attention recently.
Products will be targeting the US$3.5 billion hair loss market in the U.S.
Cellmid Ltd has received commitments to raise $3 million.
Admedus continues to implement numerous cost savings and has made significant improvements in its sales and marketing globally.
OncoSil Medical Ltd (ASX:OSL) ended the September quarter with $13.8 million in cash, and during the period delivered milestones.
Admedus Ltd has produced positive headline results.
OncoSil has received a Buy rating and $0.42 per share price target from Wilsons Research.
VascuCel will be targeting the $500 million global vascular repair market.
Surpassing $1 million in quarterly sales on the back of 30% growth compared to the September quarter in 2015 is a significant achievement for Cellmid.
Cellmid has received results from a pre-clinical collaboration with Complutense University in Spain that suggests the company’s midkine antibodies can be used to treat a type of brain cancer.The results of the study add to Cellmid’s already significant intellectual property midkine assets ready for clinical...
Entry into the Russian market for Bronchitol is a significant achievement for the company as it looks to expand the drug’s customer base and increase its potential to generate revenue.
OncoSil is a clinical-stage medical device company seeking to provide a new medical radiation treatment for cancer subjects.
Market activity in the past has already confirmed that the treatment of NASH is one of the hottest areas in biotech and Allergan’s takeover bid for Tobira has only added fuel to the fire.
Compumedics is an international leader in medical devices for sleep, brain and ultrasonic blood-flow monitoring.
Cellmid has been issued a Notice of Allowance by the European Patents Office for a patent similar to already granted patents in Japan and the U.S.